MYD88 L265P somatic mutation in Waldenström's macroglobulinemia.

By S. Treon, Lian Xu, Guang Yang, Yangsheng Zhou, Xia Liu, Yanglin Cao, P. Sheehy, R. Manning, C. Patterson, C. Tripsas and 9 more. New England Journal of Medicine, 2012

1,317 citations recorded by the source corpus.

Subfields: Genetics, Immunology, Molecular Biology

View Paper: https://www.semanticscholar.org/paper/7bbbc40de32d657f68e22c75cf91add3a67efcd9

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

1. Simar Pal Singh
2. Floris Dammeijer
3. R. Hendriks

Citations in the corpus

• The 2016 revision of the World Health Organization classification of lymphoid neoplasms. (2016, neutral): “Similarly, the 2008monograph noted that “no specific chromosomal or oncogene abnormalities are recognized” in lymphoplasmacytic lymphoma (LPL); however, we now know that about 90% of LPL or Waldenström macroglobulinemia (LPL plus an immunoglobulin M [IgM] paraprotein) have MYD88 L265P mutations.(35)”
• Integrated genomic analysis identifies recurrent mutations and evolution patterns driving the initiation and progression of follicular lymphoma (2013, neutral): “Four of the five MYD88 mutations identified were restricted to the transformation biopsy, of which none harbored the L265P mutation common to other B-cell lymphomas 30,37 (Supplementary Fig.”
• Role of Bruton’s tyrosine kinase in B cells and malignancies (2018, background): “The majority of WM patients have a somatic leucine to proline substitution at position 265 of MyD88 (MyD88) [155].”